Plaque Research Today is a free monthly online journal that collates and summarizes the latest research about Plaque, including details on dentistry, brushing, oral hygiene, mouthwash.

Abeta42 is essential for parenchymal and vascular amyloid deposition in mice.

McGowan E, Pickford F, Kim J, Onstead L, Eriksen J, Yu C, Skipper L, Murphy MP, Beard J, Das P, Jansen K, Delucia M, Lin WL, Dolios G, Wang R, Eckman CB, Dickson DW, Hutton M, Hardy J, Golde T

Department Neuroscience, Mayo Clinic College of Medicine, Jacksonville, FL 32224, USA. mcgowan.eileen@mayo.edu

Considerable circumstantial evidence suggests that Abeta42 is the initiating molecule in Alzheimer's disease (AD) pathogenesis. However, the absolute requirement for Abeta42 for amyloid deposition has never been demonstrated in vivo. We have addressed this by developing transgenic models that express Abeta1-40 or Abeta1-42 in the absence of human amyloid beta protein precursor (APP) overexpression. Mice expressing high levels of Abeta1-40 do not develop overt amyloid pathology. In contrast, mice expressing lower levels of Abeta1-42 accumulate insoluble Abeta1-42 and develop compact amyloid plaques, congophilic amyloid angiopathy (CAA), and diffuse Abeta deposits. When mice expressing Abeta1-42 are crossed with mutant APP (Tg2576) mice, there is also a massive increase in amyloid deposition. These data establish that Abeta1-42 is essential for amyloid deposition in the parenchyma and also in vessels.

Published 25 July 2005 in Neuron, 47(2): 191-9.
Full-text of this article is available online (may require subscription).

© 2004-2008 Plaque Research Today. All Rights Reserved.